Tanke Biosciences Corp Announces Appointment of Vincent Renz as Chief Executive Officer and Member of the Board of Directors
Tanke Biosciences Corp (OTC: TNBI) has appointed Vincent Renz as Chief Executive Officer and Board Member, effective February 9, 2025. Renz brings over 30 years of C-Suite leadership experience, having served in executive roles at eResearch Technology, NewCardio, Clinphone, and Computron Software.
Most recently, Renz founded Straight4ward Advisory Services and joined Brand Craft Holdings in 2024 as an advisor. He holds a BBA in Finance from Notre Dame and an MBA from Indiana University's Kelley School of Business. The company's COO, Tom Stein, emphasized that Renz's expertise will be leveraged to partner and invest in scalable businesses.
TNBI positions itself as an emerging diversified investment vehicle focusing on growth-stage businesses that have achieved revenue traction, proof of concept, or market adoption. The company aims to provide capital and management resources to drive profitable growth and shareholder value.
Tanke Biosciences Corp (OTC: TNBI) ha nominato Vincent Renz come Amministratore Delegato e Membro del Consiglio, con effetto dal 9 febbraio 2025. Renz vanta oltre 30 anni di esperienza nella leadership a livello C-Suite, avendo ricoperto ruoli dirigenziali presso eResearch Technology, NewCardio, Clinphone e Computron Software.
Recentemente, Renz ha fondato Straight4ward Advisory Services ed è entrato a far parte di Brand Craft Holdings nel 2024 come consulente. Ha conseguito una laurea in Finanza presso Notre Dame e un MBA presso la Kelley School of Business dell'Università dell'Indiana. Il COO dell'azienda, Tom Stein, ha sottolineato che l'expertise di Renz sarà sfruttata per collaborare e investire in aziende scalabili.
TNBI si posiziona come un veicolo di investimento diversificato emergente, focalizzandosi su aziende in fase di crescita che hanno raggiunto trazione nei ricavi, prova di concetto o adozione di mercato. L'azienda mira a fornire capitale e risorse di gestione per promuovere la crescita redditizia e il valore per gli azionisti.
Tanke Biosciences Corp (OTC: TNBI) ha nombrado a Vincent Renz como Director Ejecutivo y Miembro de la Junta, con efecto a partir del 9 de febrero de 2025. Renz aporta más de 30 años de experiencia en liderazgo a nivel C-Suite, habiendo ocupado roles ejecutivos en eResearch Technology, NewCardio, Clinphone y Computron Software.
Más recientemente, Renz fundó Straight4ward Advisory Services y se unió a Brand Craft Holdings en 2024 como asesor. Tiene una licenciatura en Finanzas de Notre Dame y un MBA de la Kelley School of Business de la Universidad de Indiana. El COO de la compañía, Tom Stein, enfatizó que la experiencia de Renz será aprovechada para asociarse e invertir en negocios escalables.
TNBI se posiciona como un vehículo de inversión diversificado emergente que se centra en empresas en etapa de crecimiento que han logrado tracción en ingresos, prueba de concepto o adopción en el mercado. La empresa tiene como objetivo proporcionar capital y recursos de gestión para impulsar el crecimiento rentable y el valor para los accionistas.
Tanke Biosciences Corp (OTC: TNBI)는 2025년 2월 9일부터 Vincent Renz를 최고 경영자 및 이사회 멤버로 임명했습니다. Renz는 eResearch Technology, NewCardio, Clinphone 및 Computron Software에서 임원 역할을 수행하며 30년 이상의 C-Suite 리더십 경험을 보유하고 있습니다.
최근 Renz는 Straight4ward Advisory Services를 설립하고 2024년 Brand Craft Holdings에 고문으로 합류했습니다. 그는 노트르담 대학교에서 금융학 학사 학위를, 인디애나 대학교 켈리 경영대학원에서 MBA를 취득했습니다. 회사의 COO인 Tom Stein은 Renz의 전문성이 확장 가능한 기업과의 파트너십 및 투자에 활용될 것이라고 강조했습니다.
TNBI는 수익 실적, 개념 증명 또는 시장 채택을 달성한 성장 단계 기업에 초점을 맞춘 신흥 다각화 투자 수단으로 자리매김하고 있습니다. 이 회사는 수익성 있는 성장과 주주 가치를 촉진하기 위해 자본 및 관리 자원을 제공하는 것을 목표로 하고 있습니다.
Tanke Biosciences Corp (OTC: TNBI) a nommé Vincent Renz au poste de Directeur Général et Membre du Conseil d'Administration, à compter du 9 février 2025. Renz apporte plus de 30 ans d'expérience dans des postes de direction, ayant occupé des fonctions exécutives chez eResearch Technology, NewCardio, Clinphone et Computron Software.
Plus récemment, Renz a fondé Straight4ward Advisory Services et a rejoint Brand Craft Holdings en 2024 en tant que conseiller. Il est titulaire d'un BBA en Finance de Notre Dame et d'un MBA de la Kelley School of Business de l'Université de l'Indiana. Le COO de l'entreprise, Tom Stein, a souligné que l'expertise de Renz sera mise à profit pour établir des partenariats et investir dans des entreprises évolutives.
TNBI se positionne comme un véhicule d'investissement diversifié émergent, axé sur des entreprises en phase de croissance ayant atteint une traction en matière de revenus, une preuve de concept ou une adoption sur le marché. L'entreprise vise à fournir du capital et des ressources de gestion pour favoriser une croissance rentable et créer de la valeur pour les actionnaires.
Tanke Biosciences Corp (OTC: TNBI) hat Vincent Renz zum Chief Executive Officer und Mitglied des Vorstands ernannt, wirksam ab dem 9. Februar 2025. Renz bringt über 30 Jahre Erfahrung in der Führungsebene mit, da er in leitenden Positionen bei eResearch Technology, NewCardio, Clinphone und Computron Software tätig war.
Zuletzt gründete Renz Straight4ward Advisory Services und trat 2024 als Berater zu Brand Craft Holdings bei. Er hat einen BBA in Finanzen von Notre Dame und einen MBA von der Kelley School of Business der Indiana University. Der COO des Unternehmens, Tom Stein, betonte, dass Renzs Expertise genutzt werden wird, um Partnerschaften einzugehen und in skalierbare Unternehmen zu investieren.
TNBI positioniert sich als aufstrebendes diversifiziertes Investitionsvehikel, das sich auf Wachstumsunternehmen konzentriert, die Umsatzwachstum, Machbarkeitsnachweise oder Marktakzeptanz erreicht haben. Das Unternehmen hat sich zum Ziel gesetzt, Kapital und Managementressourcen bereitzustellen, um profitables Wachstum und den Wert für die Aktionäre voranzutreiben.
- Appointment of experienced CEO with 30+ years of C-Suite leadership
- Strategic focus on investing in revenue-generating growth companies
- CEO's track record in driving shareholder value and executing turnaround strategies
- None.
Las Vegas, NV, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Tanke Biosciences Corp (the “Company”) (OTC: TNBI) announced today that Vincent Renz has been appointed Chief Executive Officer and will join the Board of Directors, effective February 9, 2025.
Mr. Renz has over 30 years of leadership experience at C-Suite level, having served as CTO of eResearch Technology, CEO/COO of NewCardio, Inc, COO of Clinphone, Sr. Vice President, Client Services of Computron Software. Mr. Renz has served most recently as the President and Founder of Straight4ward Advisory Services – a boutique professional services company. He is experienced with driving significant value creation for shareholders and delivering on both turnaround and growth strategies. In 2024, Renz joined Brand Craft Holdings in an advisory capacity to begin building the team to identify investment opportunities.
The Company’s Chief Operating Officer, Tom Stein, stated “Leveraging Vinnie’s deep experiences and expertise in building operational excellence and public company leadership, we plan to partner and invest in businesses that are positioned to scale their proven models.” He added, “With Vinnie at the helm, we intend to assemble a seasoned management, advisory and operational team.”
Mr. Renz began his career with positions at Anderson Consulting and Deloitte focused on development and implementation of advanced technology solutions. He holds a BBA in Finance from the University of Notre Dame, as well as an MBA with a specialization in Information Technology from the Kelley School of Business at Indiana University.
Mr. Renz commented; “Over the last 40+ years, I’ve built highly efficient management teams which have enabled transformative technologies and brand development, and I look forward to replicating all of these experiences and relationships in partnering and investing in emerging growth opportunities.”
About Tanke Biosciences Corp
Tanke Biosciences Corp (OTC: TNBI) is an emerging diversified investment vehicle focused on identifying emerging, growth stage businesses, which have achieved some level of revenue traction, proof of concept, and/or customer/market adoption, in order to provide them with the capital and management resources to scale profitable growth and drive shareholder value through leadership in their respective market areas. Based in Delray Beach, Florida and Newark, New Jersey, the management, advisors and the Board of Directors of the Company bring decades of tangible leadership expertise driving strong growth in organizations of all sizes through strategic capital injection, revenue growth & expansion and operational excellence.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "should," and "will" and variations of such words and similar expressions are intended to identify such forward-looking statements. All statements in this press release pertaining to our expectations constitute forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, assumptions and uncertainties, including, but not limited to, the accuracy of our estimates regarding expenses, capital requirements and need for additional financing, our ability to operate our business and generate profits, decline in global financial markets and economic downturns, unforeseen business interruptions, and general risk factors affecting our industry.
Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. We expressly disclaim any current intention to update publicly any forward-looking statement after the distribution of this release, whether as a result of new information, future events, changes in assumptions or otherwise.
FAQ
When did Vincent Renz become CEO of Tanke Biosciences (TNBI)?
What is TNBI's new business strategy under Vincent Renz?
What is Vincent Renz's professional background before joining TNBI?
How does TNBI plan to create shareholder value under the new CEO?
